The hRFC (human reduced folate carrier) is the major membrane transporter for both reduced folates and antifolates in human tissues and tumours. The primary amino acid sequence of hRFC predicts a membrane topology involving 12 TMDs (transmembrane domains) with cytosolic oriented N-and C-termini, and a large internal loop connecting TMDs 6 and 7. Previous studies using haemagglutinin epitope insertion and scanning glycosylation mutagenesis methods verified portions of the predicted topology model, including TMDs 1-8 and the N-and C-termini of hRFC. However, the topology structure for TMDs 9-12 remains controversial. To further determine the membrane topology of the hRFC protein, single cysteine residues were introduced into the predicted extracellular or cytoplasmic loops of a fully functional cysteine-less hRFC expressed in transport impaired MtxRIIOua R 2-4 Chinese hamster ovary cells. The membrane orientations of the substituted cysteines were determined by treatments with the thiol reagents 3-(N-maleimidylpropionyl)-biocytin (biotin maleimide) and 4-acetamido-4 maleimidylstilbene-2,2 -disulphonic acid (stilbenedisulphonate maleimide; SM) or N-ethylmaleimide, combined with the cell-permeabilizing reagent SLO (streptolysin O). We found that cysteine residues placed in the predicted extracellular loops between TMDs 7 and 8 (position 301), 9 and 10 (360), and 11 and 12 (429) could be biotinylated with 200 µM biotin maleimide, and labelling could be blocked with SM. However, biotinylation of cysteines placed in the predicted intracellular loops between TMDs 8 and 9 (position 332) and TMDs 10 and 11 (position 388) was only detected after cell permeabilization with SLO and was abolished by pre-treatment with N-ethylmaleimide. These results strongly support a 12-TMD topology structure for the hRFC protein.
INTRODUCTION
The ubiquitously expressed RFC (reduced folate carrier) is the major transport system for reduced folates and classical antifolates in mammalian cells [1] [2] [3] [4] . For reduced folates such as 5-methyl and 5-formyl tetrahydrofolate, adequate rates of intracellular delivery are essential for DNA synthesis and cell proliferation. For antifolates such as Mtx (methotrexate), the level of RFC is a major determinant of antitumour activity in cultured tumour cells [3, 4] and impaired transport is a frequent mechanism of antifolate resistance in tumour models both in vitro [5] [6] [7] [8] [9] [10] and in vivo [11] . A number of other antifolate chemotherapy drugs (e.g. Pemetrexed, Tomudex) are also excellent substrates for RFC [4, 12] . The clinical importance of RFC in cancer chemotherapy was strongly implied by reports of proportional changes in RFC transcripts and Mtx uptake for B-precursor acute lymphoblastic leukaemia lymphoblasts [13, 14] and in osteosarcomas from patients [15] . In osteosarcomas, losses of Mtx transport were associated with a poor prognosis [15] .
hRFC (human reduced folate carrier) cDNAs were cloned in 1995 [16] [17] [18] [19] . By hydropathy analysis [20] of the predicted amino acid sequence, hRFC is predicted to be an integral membrane protein with up to 12 stretches of mostly hydrophobic, α-helixpromoting amino acids, with a large central linker connecting the predicted TMDs (transmembrane domains) 1-6 and TMDs 7-12, internally oriented N-and C-terminal domains, and an external N-glycosylation site at Asn-58 (Figure 1 ).
Abbreviations used: hRFC, human reduced folate carrier; TMD, transmembrane domain; Mtx, methotrexate; HA, haemagglutinin; CHO, Chinese hamster ovary; SCAM, scanning cysteine accessibility methods; SLO, streptolysin O; NEM, N-ethylmaleimide. 1 To whom correspondence should be addressed, at the Experimental and Clinical Therapeutics Program (e-mail matherly@karmanos.org).
A number of studies have shed light on the membrane topological structure of the hRFC protein. For instance, our finding of N-glycosylation of hRFC confirmed an extracellular orientation of Asn-58 (located in TMD2 in Figure 1 ) [21] . By HA (haemagglutinin) insertional mutagenesis and analysis of functional proteins, extracellular orientations were confirmed for the loops connecting TMDs 3 and 4, 5 and 6, and 7 and 8, and internal orientations were demonstrated for the loops connecting TMDs 4 and 5, 6 and 7, and 8 and 9, and for the N-and C-termini [22, 23] . By N-glycosylation scanning mutagenesis, in which Nglycosylation consensus sequences [NX(S/T)] were inserted into putative loop domains, the TMD 5/6 loop sequence was, likewise, confirmed to be extracellular [23] . However, results for TMDs 9-12 and connecting loop domains were ambiguous or inconclusive. This reflects the complete loss of transport activity for hRFCs mutated in these regions and, for the N-glycosylation mutants, an inability to distinguish a lack of glycosylation at inserted Nglycosylation consensus sites due to their cytosolic orientations from effects of spacial constraints that limit their accessibilities to oligosaccharyl transferase [24] .
Our recent expression of an epitope-tagged 'cysteine-less' hRFC (hRFC myc−his6 Cys-less) in transport-impaired CHO (Chinese hamster ovary) cells [25] suggested an alternative approach for topology mapping the carrier that would circumvent the limitations of our earlier methods. We describe herein the use of SCAM (scanning cysteine accessibility methods) for establishing the membrane topology of TMDs 7-12 and their connecting A topology model is shown for the Myc-His6-tagged hRFC protein without the C-terminal 56 amino acids. It depicts 12 TMDs, internally oriented N-and C-termini and TMD 6-7 loop domain, and an externally facing N-glycosylation site at Asn-58. Also shown are the positions of the cysteine residues inserted into the predicted extracellular and cytosolic loops of the hRFC myc−his6 Cys-less protein from TMDs 7-12, as described in the text.
loops, involving insertion of individual cysteine residues into each of the predicted extracellular and intracellular loops of hRFC myc−his6 Cys-less that can then be probed with thiol-reactive maleimide agents. Major advantages of SCAM include the highlevel expression of functional single cysteine mutants, reflecting minimal structural effects resulting from cysteine insertions, and a remarkable capacity to unambiguously establish sidedness of inserted cysteines through the use of maleimide reagents differing in membrane permeabilities and the cell-permeabilization reagent, SLO (streptolysin O). Our findings complement earlier studies of hRFC topology [22, 23] and, in combination with these prior results, they unequivocally establish a 12-TMD topological structure for hRFC. [3 ,5 ,7- 3 H]Mtx (20 Ci/mmol) was purchased from Moravek Biochemicals (Brea, CA, U.S.A.). Unlabelled Mtx was provided by the Drug Development Branch, National Cancer Institute, Bethesda, MD, U.S.A. Both labelled and unlabelled Mtx were purified prior to use, as described previously [26] . 
MATERIALS AND METHODS

Reagents
Cell culture
Transport-defective Mtx-resistant CHO cells, MtxRIIOua R 2-4 [27] , were a gift of Dr Wayne Flintoff (University of Western Ontario, London, Ontario, Canada). MtxRIIOua R 2-4 cells were grown in α-minimal essential medium with 10 % iron-supplemented bovine calf serum, penicillin (100 units/ml) and streptomycin (100 µg/ml). hRFC myc−his6 Cys-less and hRFC myc−his6 wt transfectants were derived from MtxRIIOua R 2-4 cells, as described previously [25] , and maintained in complete medium in the presence of 1.5 mg/ml G-418.
Site-directed mutagenesis
A 'wild-type' hRFC construct (designated hRFC myc−his6 wt), containing a truncated open reading frame encoding 7 of the 11 cysteines, and including both c-myc and hexahistidine epitopes at the C-terminus, was prepared by subcloning 1607 bp of hRFC coding sequence into pcDNA3.1 (−) myc-his A expression vector (Invitrogen) at the BamHI and XhoI restriction sites [25] . The hRFC myc−his6 Cys-less construct, in which all cysteines were replaced by serines, was prepared from hRFC myc−his6 wt by a PCR overlap-extension mutagenesis method [25] . hRFC myc−his6 Cys-less in pCDNA3.1 was used as the template for overlap-extension PCR to generate single cysteine mutant hRFCs. The complementary mutagenesis primers used to construct the cysteine mutants are listed in Table 1 . The forward and reverse mutagenesis primers were paired with antisense (CW9, [16, 25] . Clones were selected with G-418 (1.5 mg/ml) and G-418-resistant clones were isolated and expanded. Stable transfectants were initially screened for Mtx sensitivities by plating at low densities (10 000 cells/ml) in complete medium with dialysed fetal bovine serum and 0, 10, 50 or 200 nM Mtx. Clones exhibiting restored Mtx sensitivities compared with MtxRIIOua R 2-4 cells were assayed for [ 3 H]Mtx uptake (see below) and hRFC expression on Western blots [7, 16, 25] .
Transport assays
Uptakes of [
3 H]Mtx (0.5 µM) were measured over 10 min, as described previously [25] . Levels of intracellular radioactivity were expressed as pmol/mg protein, calculated from direct measurements of radioactivity and protein contents of cell homogenates. Protein assays were performed by the method of Lowry et al. [28] .
Biotinylation of intact cells, immunoprecipitations and Western blot analysis
CHO transfectants (1 × 10 7 cells), growing on 100 mm dishes expressing hRFC myc−his6 Cys-less and the S301C, A332C, S360C, A388C and R429C single-cysteine-substituted hRFC myc−his6 mutants, were washed three times with Dulbecco's PBS. Cells were preincubated in PBS without additions or with stilbenedisulphonate maleimide (200 µM, in PBS) at room temperature for 30 min, washed three times with PBS, and then biotinylated by incubation with biotin maleimide (200 µM, in PBS) at room temperature for 30 min. Biotin maleimide was added from a stock solution prepared in DMSO. The concentration of DMSO in the labelling buffer did not exceed 1 % (v/v). After incubation, cells were briefly treated with 2-mercaptoethanol (14 mM) to remove excess reagent and then washed twice with PBS. Cells were harvested and plasma membranes prepared as described previously [29] . For immunoprecipitation, membrane proteins were solubilized in 1 ml of cell lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 % Nonidet P40 and 0.5 % sodium deoxycholate). Insoluble material was pelleted (12 000 g, 10 min) and the supernatant was precleared for at least 3 h at 4
• C with Protein G-plus Agarose beads. The beads were again pelleted (12 000 g, 20 s), and the supernatant was incubated with anti-Myc antibody (Invitrogen) and fresh Protein G-plus Agarose beads overnight at 4
• C. The beads were washed five times with lysis buffer with 0.1 % Nonidet P-40, and eluted with 40 µl of Laemmli sample buffer [30] containing 2 % SDS. Immunoprecipitated proteins were fractionated on SDS/polyacrylamide gels [30] and electrotransferred to PVDF membranes [31] . Immunodetection of biotinylated hRFC was with peroxidase-linked streptavidin (Roche) and Lumi-Light PLUS substrate (Roche), whereas total immunoprecipitated hRFC was detected with hRFC-specific antibody [7] with standard Lumi-Light substrate (Roche).
To label internal cysteines with biotin maleimide, cells (in 100 mm culture dishes) were washed twice with cold PBS. Subsequently, 3 ml of PBS with or without stilbenedisulphonate maleimide (SM, 200 µM) or NEM (3 mM) was used to pretreat the cells at room temperature (for 30 and 5 min, respectively). Cells were then washed three times with cold PBS and permeabilized by treatment with 0.5 µg/ml SLO [32, 33] . For permeabilization, cells were washed once with ice-cold incubation buffer (20 mM Hepes, pH 7.2, 140 mM potassium glutamate, 5 mM EGTA, 5 mM MgCl 2 and 5 mM NaCl), and then incubated with 0.5 µg/ml SLO in 3 ml of incubation buffer for 10 min at 4
• C. Cells were washed once with ice-cold incubation buffer, then incubated for 20 min at 37
• C in 3 ml of incubation buffer containing 1 mg/ml BSA and 1 mM dithiothreitol. Permeabilized cells were washed with PBS and treated with biotin maleimide (200 µM), followed with membrane preparation and immunoprecipitation, as described above.
RESULTS AND DISCUSSION
Construction and functional assays of single cysteine hRFC mutants in the TMD 7-12 loop domains
A computer-generated topology model (TMPRED) [20] based on the predicted hRFC amino acid sequence is shown in Figure 1 . In this model, hRFC is depicted as an integral membrane protein with 12 TMDs, with TMDs 1-6 and 7-12 linked by a large cytosolic connecting loop, and with cytosolic oriented N-and C-temini. Portions of this model (i.e. TMDs 1-8 and the Nand C-termini) have been experimentally verified by HA epitope insertion and glycosylation scanning mutagenesis methods [21] [22] [23] . However, these methods could not convincingly establish the topology structure for TMDs 9-12 due to inherent limitations. For instance, for HA epitope accessibility methods, insertion of the 9 amino acid HA epitope did not appreciably affect plasma membrane targeting; however, many of the epitopetagged proteins were functionally inactive [22, 23] , presumably due to protein misfolding and/or the assumption of conformational states different from wild-type carrier. For glycosylation scanning mutagenesis, glycosylation status by Western blotting was used to identify extracellularly oriented domains; however, this method was not useful for unequivocally identifying cytosol-oriented domains [23] .
In our previous study, we constructed a cysteine-less hRFC, in which all cysteine residues were mutagenized to serines [25] . Functional hRFC myc−his6 Cys-less protein was expressed at high levels in transport-impaired MtxRIIOua R 2-4 CHO cells and exhibited normal plasma membrane targeting and similar transport properties to the wild-type hRFC myc−his6 wt protein. Based on prior topology studies of p-glycoprotein [34] and the glutamate transporter GLT-1 [35] , it seemed reasonable to use our cysteineless hRFC construct with SCAM and thiol-reactive agents to further explore the topological structure for the putative TMDs 7-12 in hRFC.
Accordingly, we used hRFC myc−his6 Cys-less as a template to generate a series of cysteine insertion hRFC mutants, with single cysteine residues inserted into each of the putative extracellular or intracellular loop domains for TMDs 7-12 (S301C, A332C, S360C, A388C and R429C, shown in Figure 1 ). Mutant hRFC constructs were transfected into MtxRIIOua R 2-4 CHO cells; clones were isolated and screened by cytotoxicity assays from 0 to 200 nM Mtx. Stable transfectants expressing high levels of S301C, A332C, S360C, A388C and R429C hRFCs were confirmed on Western blots (results not shown) and by direct assays of [ 3 H]Mtx uptake. As shown in Figure 2 , all the single cysteine mutants displayed 5-8-fold-increased [ 3 H]Mtx uptake over the low levels in MtxRIIOua R 2-4 cells and were essentially identical to the wild-type hRFC myc−his6 wt construct. Thus folding and membrane targeting did not seem to be adversely affected by the insertion of the single cysteine residues into the loop domains, suggesting retention of a native protein conformation identical to the wild-type carrier.
Determination of topology for TMDs 7-12 by SCAM
To establish the topological structure for TMDs 7-12 of hRFC, transfected cells expressing S301C, A332C, S360C, A388C and R429C hRFC myc−his6 were treated for 30 min with the thiol-reactive agent, biotin maleimide (200 µM), with and without the membrane-impermeant stilbenedisulphonate maleimide (200 µM). Membrane proteins were solubilized, and the c-Myc-tagged hRFC proteins were immunoprecipitated with antiMyc monoclonal antibody. The immunoprecipitates were fractionated on SDS gels, and the covalently bound biotin was detected with peroxidase-linked streptavidin. Total hRFC proteins were detected on the same blot with anti-hRFC polyclonal antibody [7] .
As shown in Figure 3 , no biotinylation signal could be visualized for hRFC myc−his6 Cys-less, although a substantial amount of hRFC protein was detected in the immunoprecipitate with hRFC antibody. Consistent with previous HA-insertion mutagenesis results for the TMD 7-8 connecting loop that established its extracellular orientation [22, 23] , S301C-hRFC myc−his6 was highly reactive towards biotin maleimide and labelling was significantly blocked with membrane-impermeant stilbenedisulphonate maleimide [34] . Thus the extracellular cysteine at position 301 is readily accessible to both of the thiol-reactive agents. Conversely, no biotinylation signal was detected with A332C hRFC myc−his6 under identical experimental conditions. This implies that the cysteine insertion at position 332 is completely inaccessible to biotin maleimide, perhaps due to the size of the reagent and/or the reducing environment in the cytosol mileau. This lack of reactivity under conditions that readily label extracellular cysteines directly supports the notion of a cytosolic orientation for the TMD 8-9 connecting loop, suggested previously by our HA-accessibility results [23] .
Biotin maleimide labelling was extended to determining the orientations of the connecting loops for TMDs 9-10, 10-11 and 11-12, corresponding to the S360C, A388C and R429C hRFC myc−his6 constructs, respectively. The S360C and R429C hRFC myc−his6 proteins were effectively labelled with biotin maleimide and, in both cases, reactivity was significantly decreased by pretreatment with equimolar stilbenedisulphonate maleimide (Figure 3) . Thus the TMD 9-10 and TMD 11-12 loop regions must have an extracellular orientations. However, the result with A388C, located in the TMD 10-11 connecting loop, was inconclusive since no labelling was detected, in spite of high levels of total hRFC protein in the immunoprecipitate (Figure 3) .
Although the results in Figure 3 suggest that biotin maleimide exhibits minimal membrane permeability during exposure to 200 µM reagent, a previous study showed that permeabilization with SLO can facilitate labelling of internal cysteines [35] . Accordingly, we treated cells expressing mutant constructs with the cysteine insertions localized to the loop domains for TMD 8-9 (A332C) and TMD 10-11 (A388C), predicted to face the cytosol, with SLO (0.5 µg/ml), prior to treatment with biotin maleimide. Cells were pretreated with stilbenedisulphonate maleimide before incubation with SLO to further verify cysteine accessibilities in the absence of permeabilization. Parallel incubations were performed with the S301C hRFC myc−his6 and hRFC myc−his6 Cys-less transfectants. Membrane proteins were immunoprecipitated as before, and levels of total hRFC and biotinylated hRFC proteins were analysed by immunoblotting. High levels of hRFC proteins were detected in the immunoprecipitates for all the transfectants (Figure 4) . Predictably, biotin maleimide labelling was negligible for hRFC myc−his6 Cys-less. For S301C hRFC myc−his6 , a high level of labelling was again detected. In striking contrast to the experiment shown in Figure 3 , when cells were permeabilized with SLO, the A332C and A388C hRFC myc−his6 mutants were all effectively labelled with biotin maleimide. Since these cysteines were not accessible to stilbenedisulphonate maleimide during the pretreatment interval, no competition for labelling was observed with this reagent ( Figure 4A ). However, labelling was abolished for A332C and A388C hRFC myc−his6 upon pretreatment with the membrane-permeable reagent NEM (Figure 4B) . Collectively, these results clearly demonstrate cytosolic orientations for the TMD 8-9 and TMD 10-11 connecting loops.
Conclusions
In conclusion, we have used SCAM with thiol-reactive maleimide reagents and functional cysteine insertion hRFC mutants to verify the topological structure for TMDs 7-12 predicted by computer hydropathy analysis. Patterns of reactivity for biotin maleimide and protection by stilbenedisulphonate maleimide for residues localized in the connecting loops for TMDs 7-8, 9-10 and 11-12 were consistent with their exofacial orientations, and labelling of A332C in the TMD 8-9 and TMD 10-11 loop regions could be achieved only by permeabilization with SLO, consistent with their cytosolic orientations.
As these studies were being completed, a related paper was published using similar methods to determine the topology of the hamster RFC [36] . Findings include extracellular orientations for positions 46 (TMD 1-2 loop), 179 (TMD 5-6), 300 (TMD 7-8), 355 (TMD 9-10) and 430 (TMD 11-12), and intracellular orientations for positions 152 (TMD 4-5), 224 (TMD 6-7) and 475 (C-terminus) [36] . While these results are consistent with our findings for TMDs 7 and 8, 9 and 10, and 11 and 12, the orientations of the loops connecting TMDs 8 and 9 and 10 and 11, identified herein as intracellular, were not established.
In combination with previous findings of N-glycosylation at Asn-58 of hRFC, and the previous results from HA-insertional and scanning glycosylation mutagenesis studies, our results strongly argue for a 12 transmembrane structure for the hRFC protein with cytosolic-facing N-and C-termini and an internal TMD 6-7 loop domain. Future studies will focus on further delineating the TMD loop junctions, and explore the critical structural and functional features of the hRFC protein, including identification of the particular domains and amino acids that directly contribute to substrate binding and membrane traverse of anionic folate and antifolate substrates. These studies should be facilitated by the availability of a functional cysteine-less hRFC [25] and an established topological structure for the carrier.
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